Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 296, Issue 3, 2009, Pages

  Enç, Feruze Yilmaz ^a,f   Öneş, Tunç ^a   Akin, H Levent ^a   Dede, Fuat ^a   Turoǧlu, H Turgut ^a   Ülfer, Gözde ^a   Bekiroǧlu, Nural ^b   Haklar, Goncagül ^a   Rehfeld, Jens F ^c   Holst, Jens J ^d   Ulusoy, Nefise B ^a,e   Imeryüz, Neşe ^a,g  

^a BOGAZICI UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AMERICAN HOSPITAL   (Turkey)

^f GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g NONE   (Turkey)

Author keywords

Brain gut axis; Cholecyctokinin; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Obesity; Pancreatic polypeptide; Peptide YY

Indexed keywords

CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; LACTONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LIPID ABSORPTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SCINTIGRAPHY; STOMACH EMPTYING; STOMACH MOTILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EATING; GLUCOSE BLOOD LEVEL; INTESTINE INNERVATION; METABOLISM; OBESITY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCINTISCANNING; STOMACH;

ADULT; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; EATING; ENTERIC NERVOUS SYSTEM; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; LACTONES; MALE; OBESITY; PEPTIDE YY; STOMACH; YOUNG ADULT;

EID: 65349151980     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90209.2008     Document Type: Article

References (41)

1. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89: 1070-1077, 1985.
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157, 2007.
3. Borovicka J, Kreiss C, Asal K, Remy B, Mettraux C, Wells A, Read NW, Jansen JB, D'Amato M, Delaloye AB, Fried M, Schwizer W. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am J Physiol Gastrointest Liver Physiol 271: G448-G453, 1996.
4. Borovicka J, Schwizer W, Guttmann G, Hartmann D, Kosinski M, Wastiel C, Bischof-Delaloye A, Fried M. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 46: 774-781, 2000.
5. Carrière F, Renou C, Ransac S, Lopez V, de Caro J, Ferrato F, de Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 281: G16-G28, 2001.
6. Degen L, Matzinger D, Drewe J, Nisslé S, Maecke H, Lengsfeld H, Hadvary P, Beglinger C. Role of free fatty acids in regulating gastric emptying and gallbladder contraction. Digestion 74: 131-139, 2006.
7. Degen L, Drewe J, Piccoli F, Gragni K, Oesch S, Bunea R, D'Amato M, Beglinger C. Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. Am J Physiol Regul Integr Comp Physiol 292: R1391-R1399, 2007.
8. Enç FY, İmeryüz N, Akin L, Turoǧlu T, Dede F, Haklar G, Tekeşin N, Bekiroǧlu N, Yegen BC, Rehfeld JF, Holst JJ, Ulusoy NB. Acarbose-induced inhibition of gastric emptying is correlated with GLP-1 response and is accompanied by augmented CCK release. Am J Physiol Gastrointest Liver Physiol 281: G752-G763, 2001.
9. Fried M, Erlacher U, Schwizer W, Löchner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A, Stalder GA, Rovati L. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Gastroenterology 101: 503-511, 1991.
10. Feinle-Bisset C, Patterson M, Ghatei MA, Bloom SR, Horowitz M. Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 289: E948-E953, 2005.
11. Feinle C, O'Donovan D, Doran S, Andrews JM, Wishart J, Chapman I, Horowitz M. Effect of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans. Am J Physiol Gastrointest Liver Physiol 284: G798-G807, 2003.
12. Froehlich F, Hartmann D, Guzelhan C, Gonvers JJ, Jansen JB, Fried M. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 41: 2404-2408, 1996.
13. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50: 1752-1762, 2007.
14. Glatzle J, Wang Y, Adelson DW, Kalogeris TJ, Zittel TT, Tso P, Wei JY, Raybould HE. Chylomicron components activate duodenal vagal afferents via a cholecystokinin A receptor-mediated pathway to inhibit gastric motor function in the rat. J Physiol 550: 657-664, 2003.
15. Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, Schmitz F, Meier JJ. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 93: 3995-3998, 2008.
16. Goedecke JH, Barsdorf M, Beglinger C, Levitt NS, Lambert EV. Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes 27: 1479-1485, 2003.
17. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 256: 357-361, 1988.
18. Hildebrand P, Petrig C, Burckhardt B, Ketterer S, Lengsfeld H, Fleury A, Hadváry P, Beglinger C. Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release. Gastroenterology 114:123-129, 1998.
19. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439, 2007.
20. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
21. Lal S, Kirkup AJ, Brunsden AM, Thompson DG, Grundy D. Vagal afferent responses to fatty acids of different chain length in the rat. Am J Physiol Gastrointest Liver Physiol 281: G907-G915, 2001.
22. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Metaanalysis: pharmacologic treatment of obesity. Ann Intern Med 142: 532-546, 2005.
23. Little TJ, Russo A, Meyer JH, Horowitz M, Smyth DR, Bellon M, Wishart JM, Jones KL, Feinle-Bisset C. Free fatty acids have more potent effects on gastric emptying, gut hormones, and appetite than triacylglycerides. Gastroenterology 133: 1124-1131, 2007.
24. Matzinger D, Gutzwiller JP, Drewe J, Orban A, Engel R, D'Amato M, Rovati L, Beglinger C. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol Regul Integr Comp Physiol 277: R1718-R1724, 1999.
25. Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B, Nauck MA. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 286: E621-E625, 2004.
26. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
27. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43, 2004.
28. O'Donovan D, Feinle-Bisset C, Wishart J, Horowitz M. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. Br J Nutr 90: 849-852, 2003.
29. O'Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilcore D, Wishart JM, Morris HA, Jones KL. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 47: 2208-2214, 2004.
30. Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to an oil/aquueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 3829-3834, 2003.
31. Raybould HE, Glatzle J, Freeman SL, Whited K, Darcel N, Liou A, Bohan D. Detection of macronutrients in the intestinal wall. Auton Neurosci 125: 28-33, 2006.
32. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 44: 991-1001, 1998.
33. Reidelberger RD, Kelsey L, Heimann D, Hulce M. Effects of peripheral CCK receptor blockade on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 284: R66-R75, 2003.
34. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55: 243-251, 2006.
35. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 85: 1411-1425, 1983.
36. Schwartz TW, Holst JJ, Fahrenkrug J, Jensen SL, Nielsen OV, Rehfeld JF, de Muckadell OB, Stadil F. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 61: 781-789, 1978.
37. Schwizer W, Asal K, Kreiss C, Mettraux C, Borovicka J, Remy B, Güzelhan C, Hartmann D, Fried M. Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol Gastrointest Liver Physiol 273: G612-G620, 1997.
38. Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 133: 1796-1805, 2007.
39. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713, 2003.
40. Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 275: G984-G992, 1998.
41. Yip RGC, Wolfe M. GIP biology and fat metabolism. Life Sci 66: 91-103, 2000.